StockNews.AI
INMB
Benzinga
27 days

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

1. Martin Shkreli predicts a 90% drop for INMB shares. 2. Shkreli cites weak Phase 1 trial data as a major concern. 3. Recent enthusiasm followed INMB's 44% surge relating to XPro1595. 4. BMF Reports supports Shkreli's critique of INMB's scientific integrity. 5. INMB shares fell by 15% on Friday ahead of Shkreli's post.

5m saved
Insight
Article

FAQ

Why Very Bearish?

Shkreli's claims and historical trends suggest significant downward pressure. Similar biotech stocks have reacted similarly to critical announcements.

How important is it?

Shkreli's influence and critical insights are closely watched, especially in biotech. His track record of accurate predictions raises concern for INMB investors.

Why Short Term?

Immediate investor sentiment may shift rapidly due to Shkreli's forecast. Short-term declines historically follow such predictions in biotech stocks.

Related Companies

Related News